One Team

Clinical Excellence: Researchers Explore Regenerative Medicine

A number of clinical trials performed during 2012 also elevated a growing national reputation for advanced research. SHVI is one of just 50 centers nationwide selected to enroll in a key national trial. The trial is investigating the efficacy of stem cells for the treatment of chronic myocardial ischemia. It is one of the few studies exploring regenerative medicine for the advancement of cardiac care.

Nurse focusing

Levine Children's Hospital participated in a key clinical trial for the drug Omegaven during 2012. The trial is part of an investigative effort to improve historically low survival rates for infants who sustain liver damage from long-term intravenous nutrition. Ricardo Caicedo, MD, a principal investigator in the study, was able to send home a healthy baby in August, after the infant responded positively to the usage of omegaven.

Mount Pleasant Hospital near Charleston participated in the "Birth Outcomes Initiative" during 2012. Sponsored by the South Carolina Department of Health and Human Services, this nationwide initiative focuses on reducing the number of babies born through induced labor prior to 39 weeks of maturation. The purpose of this initiative is to ensure that fetuses have sufficient time to develop healthy lungs, brain, liver and birth weight.

Mount Pleasant also made substantial progress in securing "Baby-Friendly Hospital" designation. This recognizes birthing centers that offer an optimal level of support for infant feeding and maternal bonding.

Several other programs achieved noteworthy recognition during 2012.

SHVI's coronary artery bypass graft program received its third consecutive three-star rating from the Society of Thoracic Surgeons.